Zevra Therapeutics Inc (NASDAQ: ZVRA) on Monday, soared 9.23% from the previous trading day, before settling in for the closing price of $9.75. Within the past 52 weeks, ZVRA’s price has moved between $6.19 and $13.16.
Annual sales at Healthcare sector company grew by 29.64% over the past five years. The company achieved an average annual earnings per share of 152.66%. With a float of $55.45 million, this company’s outstanding shares have now reached $56.14 million.
Zevra Therapeutics Inc (ZVRA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zevra Therapeutics Inc is 1.21%, while institutional ownership is 65.04%. The most recent insider transaction that took place on Sep 12 ’25, was worth 24,718. In this transaction Director of this company bought 3,175 shares at a rate of $7.79, taking the stock ownership to the 3,894 shares. Before that another transaction happened on Sep 12 ’25, when Company’s Director bought 20,000 for $7.89, making the entire transaction worth $157,800. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.69 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.41) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 152.66% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Zevra Therapeutics Inc (ZVRA) is currently performing well based on its current performance indicators. A quick ratio of 7.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.05, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.55 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Zevra Therapeutics Inc (NASDAQ: ZVRA) saw its 5-day average volume 2.13 million, a positive change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 81.98%.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 58.17%, which indicates a significant decrease from 99.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.60 in the past 14 days, which was higher than the 0.48 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.47, while its 200-day Moving Average is $8.73. Nevertheless, the first resistance level for the watch stands at $11.02 in the near term. At $11.40, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.13. If the price goes on to break the first support level at $9.91, it is likely to go to the next support level at $9.18. Assuming the price breaks the second support level, the third support level stands at $8.80.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
Market capitalization of the company is 597.84 million based on 56,135K outstanding shares. Right now, sales total 23,610 K and income totals -105,510 K. The company made 25,880 K in profit during its latest quarter, and 74,710 K in sales during its previous quarter.
